27 results about "Fat emulsions" patented technology

The invention discloses an alfacalcidol emulsion and a preparation method thereof, the pH value of the alfacalcidol emulsion is 6.5-8.0, and each 1000 ml of the alfacalcidol emulsion comprises 1-30 g of alfacalcidol, 100-300 g of oil for injection, 6-20 g of a phospholipid emulsifier, 0-20 g of poloxamer 188, 20-30 g of an osmotic pressure regulator and a proper amount of water. The preparation method of the drug-loaded fat emulsion injection comprises the following steps: preparing an oil phase; preparing a water phase; preparing a primary emulsion; performing high-pressure homogenization; adjusting the pH value; and sterilizing and storing. The alfacalcidol serves as an oil-soluble substance, can be dissolved in small oil drops (emulsion particles) of the emulsion or on an interfacial film, and can keep stable physicochemical properties and enhance the slow release performance in the storage process under certain conditions, so that the drug effect time is prolonged.

The utility model discloses a rotary filling, nitrogen charging and plugging device, which relates to the technical field of filling equipment in pharmaceutical machinery, and comprises a rack 9, a bottle conveying mechanism 2, a bottle separating mechanism 3, a nitrogen charging and plugging mechanism 4, a plug arranging mechanism 1 and a plug taking, nitrogen charging, filling and pressing mechanism 8, the bottle feeding mechanism 2 is arranged on the front side of the upper portion of the rack 9, and the bottle separating mechanism 3 is arranged on the front side of the right end of the bottle feeding mechanism 2. The nitrogen charging and plugging mechanism 4 is arranged on the rear side of the right part of the bottle conveying mechanism 2, and the plug arranging mechanism 1 is arranged on the right side of the nitrogen charging and plugging mechanism 4; the plug taking, nitrogen charging, filling and pressing mechanism 8 is arranged at the middle left part of the upper part of the rack 9, and the right part of the plug taking, nitrogen charging, filling and pressing mechanism 8 is respectively connected with the nitrogen charging and plugging mechanism 4 and the bottle conveying mechanism 2. The nitrogen filling machine has the characteristics of simple process, lower use cost, smaller occupied area of equipment, capability of greatly improving the quality of filled medicines and the like, and can be used for nitrogen filling of high-added-value products such as glucose, antibiotics, amino acid, fat emulsion, oral liquid, nutrient solution, biological agents and the like.

The invention discloses a preparation method of a fat emulsion injection with a C6-24 structure. According to the method, residual oxygen and dissolved oxygen are strictly controlled in the preparation process, unsaturated fatty acid in the structural fat emulsion injection (C6-24) is prevented from being oxidized, impurities such as peroxides, aldehydes and ketones are reduced, and the medication safety is improved; by controlling the flow rate of oil-water mixing, the emulsifying effect is improved, the uniformity of emulsion particles is improved, and the long-term stability of the injection is effectively ensured, so that the product quality is good.

A yolk phospholipid composition having a lysophosphatidyl ethanolamine content of 1% by mass or less and an amino acid content of 50 mg / 100 g or more and 500 mg / 100 g or less.

The invention belongs to the technical field of pharmaceutical preparations, and discloses a stable aprepitant injection and a preparation method thereof. The aprepitant injection comprises the following raw materials in percentage by mass: 0.5-1% of aprepitant, 8-12% of soybean oil, 8-12% of egg yolk lecithin, 0.05-2% of egg yolk phosphatidyl glycerol, 0.5-0.8% of sodium oleate, 5-8% of cane sugar, 2-4% of ethanol and the balance of water for injection, totaling 100%. The selected co-emulsifier egg yolk phosphatidyl glycerol has two hydroxyl groups at the hydrophilic end, so that the egg yolk phosphatidyl glycerol has extremely strong emulsifying performance, is well compatible with aprepitant, has a good emulsifying effect of the preparation, and can well encapsulate aprepitant, so that the dosage of egg yolk lecithin is reduced by about one third, and the stable drug-loaded fat emulsion is formed; the preparation method is suitable for industrial production, the preparation cost is low, and the accessibility of the medicine is improved.

This invention relates to a method for preparing and applying a fat emulsion injection, belonging to the field of pharmaceutical technology. The preparation steps include preparing an oil phase using egg yolk lecithin with a specific PC and PE mass ratio as an emulsifier, mixing it with an aqueous phase to obtain a colostrum, homogenizing the colostrum, and then adding sodium oleate to obtain the fat emulsion injection. The fat emulsion injection prepared by the method of this invention has the characteristics of a low SPAN value and a small number of large-diameter emulsion particles.

The embodiment of the invention discloses a fat emulsion preparation method, which comprises: (1) oil phase preparation: taking grease, and heating to obtain an oil phase; (2) preparing a water phase, namely heating water for injection, glycerol and a part of sodium hydroxide in the prescription to obtain the water phase; (3) preparing primary emulsion: mixing and shearing the oil phase and the water phase in proportion to obtain an oil-water mixed phase, circularly shearing uniformly, and filtering to obtain relatively stable primary emulsion; (4) front low-pressure homogenization: homogenizing the primary emulsion to obtain stable primary emulsion; (5) high-pressure homogenization: homogenizing the stable primary emulsion to obtain stable finished emulsion; (6) post-low-pressure homogenization: homogenizing the finished milk to obtain final milk; and (7) adding the residual sodium hydroxide in the prescription: adding the residual sodium hydroxide in the prescription into the final emulsion, and uniformly stirring to obtain the full-prescription fat emulsion.

The patent application relates to a paper-based packaging material with a carrier paper and a first coating arranged indirectly on at least one side of the carrier paper, wherein the first coating is a barrier layer and has an increased diffusion resistance to at least one substance selected from a group comprising fluid, gas, air, oxygen, carbon dioxide, nitrogen, inert gas, odorant, aromatic substance, water vapor, liquid, water, water-fat emulsion, fat, oil, mineral oil, and edible oil, odorant, flavorant, water vapor, liquid, water, water-fat emulsion, grease, oil, mineral oil, and edible oil individually or in combination, wherein the first coating is disposed between the carrier paper and a visually perceptible surface coating and directly contacts the surface coating. Furthermore, the invention relates to a package made of such a paper-based packaging material and a method of manufacturing the same.

The present application relates to a method for determining the content of impurity aluminum element in fat emulsion injection by high performance liquid chromatography. 9 mL of test sample and 1 mL of acid reagent are precisely added, heated at 80 DEG C for 30 min in a graphite digestion instrument, then heated at 100 DEG C for 1 h, the obtained product is concentrated at 120 DEG C, cooled, transferred with purified water and diluted to 10 mL, 3 mL of n-heptane is added for extraction, the solution is separated into two layers by standing, the water phase is filtered, and the filtrate is obtained as a test sample solution. 0.1 mL of aluminum element series control solution, blank control solution, test sample solution and blank test sample solution are precisely taken respectively, 0.9 mL of derivative reagent is precisely added, mixed, then injected into a liquid chromatograph respectively, and the chromatogram is recorded. The method of the present application selects a suitable demulsification acid solvent to destroy the structure of fat emulsion oil-in-water, release the wrapped impurity aluminum element, and obtain a clear solution at the same time, which meets the requirements of high performance liquid chromatography injection.

The application belongs to the technical field of medicine extraction and medicine detection, and discloses a detection method of related substances in palonosetron-containing fat emulsion injection. Methanol is used as a main demulsifier, and a sodium dihydrogen phosphate buffer salt solution with a suitable ionic strength is used for assistance, so that full demulsification is realized under the premise of not introducing a third organic phase; a water bath evaporation and redissolution method is used to enrich target components in the solution after demulsification, so that good chromatographic behavior and complete recovery of the target components are ensured, and the detection sensitivity is effectively improved. The palonosetron and related impurities have good separation degree, the method is simple to operate, accurate to measure, and strong in specificity, and is suitable for the determination of palonosetron related substances in rolapitant palonosetron fat emulsion.

Provided are an alphaxalone fat emulsion injection and a method for preparing same. The alphaxalone fat emulsion injection comprises alphaxalone and a pharmaceutically acceptable salt thereof, an oil phase, an emulsifier, a co-emulsifier, an osmotic pressure regulator, a stabilizer, a pH value regulator, and water for injection.

A yolk phospholipid composition having a lysophosphatidyl ethanolamine content of 1% by mass or less and an amino acid content of 50 mg / 100 g or more and 500 mg / 100 g or less.

This invention discloses a method for detecting the encapsulation efficiency of dexamethasone palmitate injection, belonging to the technical field of encapsulation efficiency detection. The method involves mixing dexamethasone palmitate injection with a solvent for extraction; the dexamethasone palmitate injection comprises a fat emulsion and free dexamethasone palmitate; after extraction, the fat emulsion and free dexamethasone palmitate are separated, and the encapsulation efficiency is calculated by quantitative analysis using HPLC; the polarity of the solvent is similar to that of the dexamethasone palmitate. This invention utilizes the principle of "like dissolves like" to develop a method for determining the encapsulation efficiency of dexamethasone palmitate injection extracted with an organic solvent. This method effectively separates the fat emulsion from the free dexamethasone palmitate while ensuring that the structure of the fat emulsion is not damaged during the measurement process, thus avoiding falsely low encapsulation efficiency due to drug leakage.

A method for determining the contents of linoleic acid and α-linolenic acid in a fat emulsion injection. The method comprises: demulsifying a fat emulsion, subjecting fatty acids to methyl esterification, separating methyl ester compounds of linoleic acid and α-linolenic acid by using gas chromatography, and performing quantitative calculation to obtain the contents of linoleic acid and α-linolenic acid. By means of demulsifying the fat emulsion and subjecting linoleic acid and α-linolenic acid to methyl esterification, followed by separation of the resulting methyl ester compounds, the contents of linoleic acid and α-linolenic acid in the fat emulsion can be accurately and rapidly determined. Moreover, the method involves a simple pretreatment process and high precision, realizing an efficient, rapid and accurate method for detecting the contents of linoleic acid and α-linolenic acid in a fat emulsion injection.

The invention relates to the field of medical dressing patches, and particularly discloses a method for preparing a wet type dressing patch based on a fat emulsion technology and the prepared wet type dressing patch, and the method comprises the following steps: S1, dissolving sodium guaiazulene sulfonate, phospholipid A, a radix astragali extract and a radix platycodonis extract in water to prepare a water-phase solution; s2, mixing olive oil, phospholipid B and the radix arnebiae seu lithospermi extract, heating and stirring to obtain an oil phase solution; s3, adding the oil phase solution into the water phase solution, and shearing to obtain a primary emulsion solution; s4, homogenizing the primary emulsion solution to obtain fat emulsion liquid medicine; s5, soaking a sponge carrier in the fat emulsion liquid medicine, and drying to obtain a wet dressing patch; the invention further discloses the wet dressing patch prepared by adopting the method. The preparation method has the characteristics that the prepared wet dressing patch can effectively promote wound healing, has good air permeability and antibacterial performance, and can uniformly release medicine components.

The present disclosure provides methods for decreasing injuries associated with intraoperative hypotension by intravenously administering to a subject a therapeutically effective amount of a fat emulsion, following a period of intraoperative hypotension and after the subject's mean arterial blood pressure has recovered. The disclosure also provides methods for preventing injuries associated with intraoperative hypotension, particularly for surgical candidates that have an increased risk for intraoperative hypotension. Non-limiting examples of injuries contemplated herein include myocardial injury, myocardial infarction, and acute kidney injury.

This utility model discloses an auxiliary squeezer for fat emulsion amino acid glucose injection, including a main roller shaft, and a first pressure roller and a second pressure roller parallel to the main roller shaft. The end of the first pressure roller is connected to the end of the main roller shaft via a first connecting rod, and the end of the second pressure roller is connected to the end of the main roller shaft via a second connecting rod. At least one end of the second connecting rod is pivotally connected to the second connecting rod or the main roller shaft. The main roller shaft is provided with a groove matching the thickness of the injection bag, and the groove extends axially to form an elongated structure. This utility model provides an auxiliary squeezer for fat emulsion amino acid glucose injection, which can simulate the action of existing manual squeezing, squeezing the bag from the edge of the injection bag, which is conducive to the rapid peeling of the seal between the chambers. At the same time, the fingers of the medical staff are not squeezed, thus protecting the fingers of the medical staff.

The application relates to the field of simulation devices and application methods of pharmacokinetics, in particular to a device for simulating an in-vivo two-compartment model and a method for accurately predicting the detoxification effect of fat emulsion, and independently designs a two-pool four-pump device, which comprises two pools for simulating a two-compartment system and four pump devices serving as a driving system for transporting liquid. The device has the characteristics of uniform stirring and constant system temperature, and adopts a dynamic environment of liquid continuous flow to simulate the distribution and elimination of drugs in the body. Based on the phenomenon that liposoluble drug molecules can be captured by fat emulsion and the capturing degree is positively correlated with the lipophilicity of the drugs, fat emulsion with adjustable flow rate is injected on the basis of the two-pool four-pump device, the change of the drug concentration is detected by using a high-performance liquid chromatograph, the dose-effect relationship between the fat emulsion infusion speed and the capturing effect of drugs with various properties is established, and the accuracy of the dose-effect relationship in in-vivo prediction is verified through animal experiments.

This invention discloses a bilayer hydrogel scaffold, its preparation method, and its applications, relating to the field of medical repair materials technology. The bilayer hydrogel scaffold comprises upper and lower hydrogel layers made of materials with different degradation rates and mechanical properties, both layers being loaded with nano-fat emulsions. The thickness of the upper hydrogel layer is greater than or equal to the thickness of the lower hydrogel layer. This invention utilizes the differences in degradation rates and mechanical properties of different materials to prepare a bilayer hydrogel scaffold, integrating functions such as promoting nerve repair, promoting vascular activity, and promoting bone activity. It achieves the effect of simultaneously adapting to two different pathological environments within the same implant, thereby avoiding secondary surgery for patients. This invention utilizes photocrosslinking technology to achieve integrated molding of the bilayer structure, ensuring a strong interface bond between the upper and lower layers and eliminating the risk of delamination. Simultaneously, the preparation process is controllable and highly customizable, allowing for flexible adjustment of the scaffold's size and pore structure according to the clinical defect morphology.

The invention relates to the food and pharmaceutical industry, namely to food products, functional nutrition products, dietary supplements, beverages, and represents a method for improving the digestibility of functional nutrition products using an inert gas. The method for improving the digestibility of products using the inert gas includes a mixing of the inert gas with a functional nutrition product, wherein the functional nutrition products used are a fat emulsion, oils, water-soluble ingredients used in manufacturing of nutrition products, dietary supplements, beverages, and the active ingredient is at least one gas from the group including xenon, krypton, the gas content in the nutrition product being from 5 ml / l to 2.8 l / l, or a mixture thereof in various ratios. The use of the invention makes it possible to enhance the digestion of functional nutrition products.

The present invention relates to a pharmaceutical composition containing an etomidate derivative, a pharmaceutically acceptable salt thereof, a prodrug thereof, or an isotope derivative thereof, and a use thereof as an anesthetic, sedative and / or hypnotic drug for animals or humans. The pharmaceutical composition is a fat emulsion injection, the encapsulation efficiency of the pharmaceutical composition is stabilized at 90% or above to 98%, the particle size is small and concentrated in distribution, the content of related substances (including acid impurities and total impurities) is lower than that of an etomidate emulsion injection, and the stability, bioavailability, safety and effectiveness of the pharmaceutical composition are better. In the aspect of clinical application, compared with etomidate, the etomidate derivative has the advantages that the clinical dosage is reduced, the anesthesia, sedation and / or hypnosis duration on animals or human beings under the condition of a relatively low dosage is longer than that of an etomidate group with a relatively high dosage, the recovery time is overall better than that of the etomidate group, the adverse reaction is obviously reduced, and the etomidate derivative has a good clinical application prospect. The problems that the etomidate anesthetic is large in dosage and large in side effect are solved, and discomfort of a patient in the treatment process can be remarkably reduced.

The present invention relates to the field of hemodialysis and peritoneal dialysis, in particular to a fat emulsion dialysate, and preparation method and the use thereof. Provided in the present invention is a fat emulsion dialysate, comprising a long-chain fat emulsion oil, a medium-chain triglyceride, an anti-oxidant, sodium oleate, glycerin, phospholipid, and a solvent. Compared with traditional dialysis, the fat emulsion dialysate provided by the present invention has a better advantage for protein-bound toxin removal. In addition, the fat emulsion dialysate not only has a simple preparation method and a low cost, but also has good stability and safety, and remains stable at room temperature for 14 days without obvious precipitation. Thus, the fat emulsion dialysate can become a hemodialysis dialysate or peritoneal dialysate with broad application prospects, and has good industrialization prospects.

The invention relates to a structural fat emulsion injection. The structural fat emulsion injection comprises structural triglyceride, egg yolk lecithin, sodium oleate, glycerol and water for injection. The fat emulsion injection with the structure can reduce the use of egg yolk lecithin from animals, and has excellent stability and good safety.

METHOD FOR EXTRACTING OIL FROM MICROBIAL BIOMASS ABSTRACT The current invention relates to a method for extracting oil from a microbial biomass comprising the steps of: mechanically lysing a microbial biomass, thereby obtaining a fat-in-water emulsion; churning the fat-in-water emulsion, thereby obtaining a water-in-fat emulsion and an aqueous phase; and centrifuging the water-in-fat emulsion, thereby obtaining a microbial 0” containing fraction.

This invention discloses an alfasalol fat emulsion injection and its preparation method. The alfasalol fat emulsion injection comprises alfasalol and its pharmaceutically acceptable salts; an oil phase, an emulsifier, an osmotic pressure regulator, a stabilizer, a pH adjuster, and water for injection. The oil phase of this application is a 1:1 mixture of soybean oil and medium-chain oil, which can significantly reduce particle size and the occurrence of allergies, and has good stability.

The present disclosure relates to a pharmaceutical composition comprising an SMTP derivative. Specifically, the present disclosure relates to a fat emulsion, comprising: a compound represented by formula I or a pharmaceutically acceptable salt thereof, an oil component, water, and a first emulsifier. The pharmaceutical composition can be better applied in clinic practice.

This invention relates to the pharmaceutical field, specifically to a paeoniflorin-6-O'-benzenesulfonate fat emulsion injection with a specific compound carrier and its preparation method. The formulation of this invention comprises the following components in the indicated mass ratios: 1.5%–5.5% solid dispersion, 10%–30% oil phase solvent, 3%–10% isotonic adjuster, 0.1%–1% pH adjuster, and the balance being water for injection; the solid dispersion is formed by mixing paeoniflorin-6-O'-benzenesulfonate with a compound carrier. This invention first prepares paeoniflorin-6-O'-benzenesulfonate into a solid dispersion, and then prepares a fat emulsion to increase the lipid solubility of paeoniflorin-6-O'-benzenesulfonate, thus solving the problem that paeoniflorin-6-O'-benzenesulfonate is insoluble in the oil phase and cannot be used to prepare fat emulsion injections. It also improves the stability and membrane permeability of easily degradable paeoniflorin-6-O'-benzenesulfonate, reducing the dosage. The prepared particles are smaller, more stable, have higher drug loading, and higher encapsulation efficiency. Furthermore, it solves the problem of slow absorption in the gastrointestinal tract, and by using injection, it significantly improves bioavailability.